Key Highlights

  • Second-quarter Revenue reached $46.5 million, missing the $49.9 million consensus estimate by nearly 7%, though up 29% quarter over quarter.
  • Adjusted Earnings Per Share was negative $0.52, missing the negative $0.32 consensus estimate by more than 62%.
  • Full-year 2026 revenue guidance was raised to $220 million to $230 million, with July preliminary results showing a record $20.9 million in monthly revenue.
  • The company secured a $1 billion growth financing Facility from General Catalyst to fund approximately 70% of Acquisition Marketing spend.

A Wide Miss Alongside Accelerating Sequential Momentum

Prenetics Global Limited (NASDAQ:PRE) reported second-quarter total revenue of $46.5 million, missing the $49.9 million consensus estimate by nearly 7%, though representing 29% quarter-over-quarter growth and a 3.9 times increase year over year, with 65% gross Margin contributing $45 million. Adjusted earnings per share of negative $0.52 missed the negative $0.32 consensus estimate by more than 62%, a wider loss than expected even as the top-line trajectory continued accelerating sequentially.

Despite the earnings miss, July preliminary results showed record monthly revenue of $20.9 million, 4.3 times growth over the prior year, along with a customer acquisition cost of $239, down 21% from the second quarter, and the company's first-ever positive consolidated adjusted free Cash Flow month, suggesting momentum has continued building beyond the reported quarter.

Guidance Raise Suggests Confidence Despite the Earnings Shortfall

Management raised full-year 2026 revenue guidance to $220 million to $230 million, up from a prior $215 million to $222 million, while issuing third-quarter guidance calling for total revenue of $63 million to $64 million, including $61.5 million to $62.5 million from the IM8 consumer health brand. Second-half adjusted EBITDA loss is now expected to narrow to $8 million to $12 million, from a first-half loss of $24.6 million, with the company guiding to a 2027 exit annualized run rate of roughly $300 million, or approximately $25 million per month.

This combination of a miss alongside raised guidance suggests the earnings shortfall may reflect timing or investment-related factors rather than deterioration in the underlying growth trajectory, a reading reinforced by the sequential acceleration evident in the July preliminary figures.

Unit Economics showed meaningful improvement, with gross profit-to-acquisition cost returns improving to $1.52 per dollar spent, up from $1.44 through first-quarter cohorts, while 87% of revenue is now recurring, with active subscribers reaching 140,000 and retention outperforming several established competitors.

New Product Launches and Capital Access Support the Growth Runway

Prenetics secured a $1 billion growth financing facility from General Catalyst, funding approximately 70% of acquisition marketing spend, ending the quarter with $109.4 million in cash and financial assets. The company also executed a $40 million share buyback, with $36.1 million in net cash impact, while reporting a net loss of $9 million, down 45% year over year.

The company announced two new product launches not yet reflected in guidance: IM8 Hydration, targeting a $37 billion market in the fourth quarter of 2026, and premium gummies targeting a $25 billion category in the first quarter of 2027, both backed by three ongoing clinical trials, including one at Mayo Clinic, with results expected between the first and third quarters of 2027. The company welcomed a new board member and highlighted no near-term plans for retail expansion or acquisition exit.

Some factors could influence the pace of continued improvement. The durability of recent operating cost reductions, achieved despite doubling marketing spend and supported by a lean AI-native organizational structure, will likely be tested as the company scales toward its 2027 run rate target.

Conclusion

Prenetics' second quarter reflected a divergence between a wide miss on reported revenue and earnings and a clearly accelerating underlying growth trajectory, reinforced by record July preliminary results and raised full-year guidance. The durability of this momentum is likely to depend on continued improvement in unit economics and subscriber retention, alongside successful execution of upcoming product launches not yet reflected in current guidance.